Fortress Biotech’s Cyprium Agrees to $205M Sale of FDA Priority Review Voucher
Fortress Biotech’s subsidiary Cyprium entered an agreement to sell its FDA priority review voucher for $205 million, securing a substantial non-dilutive cash infusion. The proceeds will bolster the company’s balance sheet and fund advancement of its late-stage clinical pipeline programs.
1. Voucher Sale Agreement
Cyprium Therapeutics, a subsidiary of Fortress Biotech, entered into a definitive agreement to sell its FDA priority review voucher for $205 million. Under the terms, Fortress will receive the full payment upon completion of the transaction.
2. Financial Impact
The $205 million represents non-dilutive financing that significantly strengthens Fortress Biotech’s cash position. This capital injection is expected to extend the company’s operational runway and reduce reliance on equity fundraising.
3. Pipeline Funding Plans
Fortress Biotech intends to allocate the voucher sale proceeds to advance its late-stage clinical candidates in rare diseases and oncology. The funds will support ongoing Phase 2 and Phase 3 studies across multiple programs.
4. Priority Review Voucher Context
FDA priority review vouchers are granted for approvals of treatments targeting rare or neglected diseases and can be sold to other companies. This transaction marks Fortress Biotech’s first monetization of such a voucher, demonstrating a new financing avenue.